Am J Transplant, Volume 18, Suppl 3 Archives - Page 113 of 211 - ATC Abstracts

2018 American Transplant Congress
Reduction in Circulating CD19⁺CD24⁺CD27⁺ Regulatory B Cell Frequency Predicts Acute Rejection in Liver Transplant Patients
H. Zhou, Z. Rao, Y. Lu, J. Rao, J. Gu, L. Lu, Y. Xia.
Liver Transplant Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: Accumulating evidence suggests that regulatory B cells (Bregs) play an important role in modulating inflammation and autoimmune diseases. However, whether Bregs regulate acute liver…
2018 American Transplant Congress
Human Urine-Derived Stem Cells Protect Renal Function by Releasing miR-129-5p Which Targets High-Mobility Group Box-1 (HMGB1) in Rat Ischemia Reperfusion Injury Model
L. Liu, X. Li, Q. Su, Z. Bi, H. Huang, C. Wang.
Organ Transplant Center, The First Affiliated Hospital of Sun Yet-sen University, New York, NY, China.
Objective: This study investigated the protective effect of human urine-derived stem cells (USCs) on renal ischemia reperfusion injury (IRI) in rats. Methods: Human USCs was…
2018 American Transplant Congress
Geographic Variation in the Treatment of Adult Heart Transplant Candidates in the US
W. Parker,¹ M. Churperk,¹ D. Hedeker,¹ E. Huang,¹ E. Garrity,¹ M. Siegler,¹ A. Anderson.²
¹University of Chicago, Chicago, IL; ²Northwestern University, Chicago, IL.
The current priority ranking system for US heart transplant candidates is based on treatment intensity which may encourage the overtreatment of relatively stable candidates. We…
2018 American Transplant Congress
Lymphocyte Proportions Post Thymectomy Are Associated with Allergic Disorders in Heart Transplanted Children
T. Kim,¹ L. Ionescu,^1,2,3 N. Avdimiretz,⁴ M. Larsen,^1,2,3 F. Murdoch,^1,2 B. Motyka,^1,2,3 S. Gilmour,^1,2 L. West,^1,2,3 S. Urschel.^1,2,3
¹Pediatrics, University of Alberta, Edmonton, AB, Canada; ²Stollery Children's Hospital, Edmonton, AB, Canada; ³Alberta Transplant Institute, Edmonton, Canada; ⁴The Hospital for Sick Children, Toronto, Canada.
Background: Allergic disorders are more common in pediatric heart transplant (HTx) recipients than non-transplanted children, with young age at HTx and thymectomy being risk factors.…
2018 American Transplant Congress
Combined Heart–Kidney Compared to Isolated Heart Transplant in Patients with Chronic Kidney Disease – A Single Center Experience
D. Gauvin, A. Bhalla, W. McCallum, A. Vest, N. Goyal.
Tufts University School of Medicine, Boston, MA.
Background: Severe irreversible renal dysfunction has been a contraindication for heart transplant (HTx); however, combined heart-kidney transplant (HKTx) is an accepted therapeutic option for concomitant…
2018 American Transplant Congress
Analysis of Human Islet Damage during In Vitro Culture Using miRNA 375
Y. Shindo,¹ M. Levy,^1,2 M. Kanak.¹
¹Department of Surgery, School of Medicine, Virginia Commonwealth University, Richmond; ²Hume-Lee Transplant Center, VCU Health System, Richmond.
BackgroundIslet culture prior to transplantation has been shown to facilitate recovery, reduce immunogenicity, suppress exocrine contamination and provides flexibility for evaluation of islets and preparation…
2018 American Transplant Congress
DonorNet and Biases in Decision-Making: An Organ Offer Simulation Study
D. Stewart,¹ J. Lindemans,² J. Schold,³ H. McGehee,¹ J. Kessler,⁴ C. Sullivan,⁴ M. Turner,² K. Mekeel,⁵ C. Berg,² R. Stratta,⁶ R. Formica,⁷ L. Ratner,⁸ D. Klassen,¹ B. Shepard.¹
¹UNOS, Richmond; ²Duke, Durham; ³CCF, Cleveland; ⁴Wharton, Philadelphia; ⁵UCSD, San Diego; ⁶Wake Forest, Winston-Salem; ⁷Yale, New Haven; ⁸Columbia, NY.
Background: Behavioral science research has revealed that the way information is presented can impact decision-making. UNOS has developed a DonorNet-like simulation tool to send hypothetical…
2018 American Transplant Congress
Early Outcomes and Risk Factors after Five Years of a Nationwide Strategy for Kidney Transplantation with Controlled Circulatory Death Donor (cDCD)
J. Portoles,^1,2 M. Perez Saez,² D. Hernandez,² J. Juega,² F. Moreso,² N. Maruri,² P. Lopez,^1,2 E. Melilli,² D. Navarro,² E. de Souza,² J. Ruiz,² M. Mazuecos,² A. Gutierrez,² I. Perez-Flores,² D. Janeiro,^1,2 J. Pascual.²
¹Nephrology, H Puerta de Hierro, Madrid, Spain; ²Nephrology, Spanish Multicentre Sentra-GEODAS Group, Madrid, Spain.
Study: prospective multicentre, systematic inclusion of every kidney transplants-KTx from controlled donation after circulatory death (cDCD) at joined units. Local center surgical and immunosuppressive protocols.Background:…
2018 American Transplant Congress
Differences in Rejection and Clinical Outcomes in Obese versus Non-Obese Renal Transplant Recipients Receiving Basiliximab Induction Immunosuppression
J. Benken,¹ C. Kane,² A. Lichvar,¹ E. Benedetti.¹
¹University of Illinois at Chicago, Chicago, IL; ²University of Northwestern Memorial Hospital, Chicago, IL.
Introduction: Basilixiab is a fixed-dose IL-2 receptor antagonist that is used for non-lymphodepleting induction therapy. The impact of obesity on basiliximab pharmacokinetics and pharmacodynamics is…
2018 American Transplant Congress
Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
E. Loncharic, A. Dodson, K. Gutierrez.
Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.
Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…